Navigation Links
Generic Pharma Partnering Yearbook 2013 - Access to the Partnering Deals and Agreements Globally
Date:1/31/2013

MUMBAI, January 31, 2013 /PRNewswire/ --

The Generic Pharma Partnering Yearbook 2013 report series provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2012.

     (Logo: http://photos.prnewswire.com/prnh/20130128/590935)

Get an overview of the yearbook at http://www.bharatbook.com/GenericPharmaPartneringYearbook.html

Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide.

The initial chapters of this report provide an orientation of 2012's dealmaking and business activities.

Chapter 1 provides an overview of the trends in dealmaking during 2012 covering trends by deal type, stage of development, technology type and therapeutic indication.

Chapter 2 provides a review of the leading deals during 2012. Deals are listed by headline value, signed by bigpharma and bigbiotech, and most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 3 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of 2012 deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 4 provides a comprehensive directory of all partnering deals announced during 2012. 
The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), therapy area and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma partnering and dealmaking during 2012. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2012.

Key benefits

Generic Pharma Partnering Yearbook 2013 series provides the reader with the following key benefits:

  • In-depth understanding of recent dealmaking trends during 2012
  • Comprehensive access to all deals entered into by the world's biopharma companies during 2012
  • Detailed access to actual partnership deals and contracts entered into by the leading fifty bigpharma companies
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Generic Pharma Partnering Yearbook 2013 series is intended to provide the reader with an in-depth understanding and access to parthering and M&A trends and structure of deals entered into by leading companies worldwide.

Generic Pharma Partnering Yearbook 2013 includes:

  • Trends in dealmaking in the biopharma industry during 2012
  • Comprehensive directory of partnering deals in 2012
  • Links to online access to all deals and alliances
  • The leading partnering deals by value in 2012
  • Most active partnering dealmakers during 2012

In Generic Pharma Partnering Yearbook 2012 series the partnering and M&A deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Therapy area
  • Technology type

Each deal title links via Weblink to an online version of the deal record at Current Agreements and where available, the contract document, providing easy access to each contract document on demand.

Get more information regarding this report at -

http://www.bharatbook.com/GenericPharmaPartneringYearbook.html

Executive Summary

Chapter 1 - Trends in dealmaking during 2012
1.1. Bigpharma dealmaking activity
1.2. Partnering by deal type
1.3. Partnering by industry sector
1.4. Partnering by stage of development
1.5. Partnering by technology type
1.6. Partnering by therapy area

Chapter 2 - Leading deals during 2012
2.1. Introduction

2.2. Top deals by value during 2012


Chapter 3 - Bigpharma deals during 2012

3.1. Introduction

3.2. How to use bigpharma partnering deals

3.3. Bigpharma partnering company profiles for 2012

Abbott; Actavis; Actelion; Allergan; Amgen; Aspen; Pharmacare; Astellas; AstraZeneca; BaxterInternational; Bayer; Biogen Idec;Boehringer Ingelheim; Bristol-Myers Squibb; Celgene ;CSL; DaiichiSankyo; Dainippon Sumitomo; Eisai ; Eli Lilly; Endo Pharmaceuticals ; Forest Laboratories; Galderma ;Gilead Sciences; GlaxoSmithKline ; Grifols ;Hospira;Johnson & Johnson; Kyowa Hakko Kirin;Lundbeck ; Menarini;Merck & Co;Merck KGaA;Mitsubishi Tanabe;Novartis ;Novo Nordisk;Otsuka; Pfizer; Purdue;Roche; Sanofi ; Servier; Shionogi;Shire; Takeda;Teva; Valeant;Warner Chilcott;Watson

Chapter 4 - Partnering deals directory 2012

4.1. Introduction 

4.2. Company A-Z

4.3. By deal type

4.4. By stage of development

4.5. By technology type

4.6. By therapy area

Table of figures

Figure 1: Bigpharma - top 50 - January to December 2012
Figure 2: Bigpharma deal frequency - 2012
Figure 3: Partnering by deal type during 2012
Figure 4: Partnering by industry sector during 2012
Figure 5: Partnering by stage of development during 2012
Figure 6: Partnering by technology type during 2012
Figure 7: Partnering by therapy area during 2012
Figure 8: Top deals by value during 2012

Request for sample pages - http://www.bharatbook.com/RequestSample.asp?pid=363918

Related Reports on Generic Pharma:

Specialty Pharma Partnering Yearbook 2013

Bigpharma Partnering Yearbook 2013

Generic Pharma Partnering Yearbook 2013

Pharmaceutical Partnering Yearbook 2013

Pharma Leader Series: Top 50 Generic Drug Manufacturers 2012-2022

International Directory of Generics Companies 2013

About Bharat Book Bureau

Bharat Book Bureau is the leading market research information aggregator that provides market research reports, industry analysis, company profiles, business reports, country reports, newsletters and online databases. Our clients include Corporate, Consulting firms, and Academic Institutions and Government departments across the globe.. Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. The market research reports we provide, help global companies examine the different markets before setting up a business or expanding into different countries across the world. They give a complete perspective on the current market scenario, trends, segments and future outlook.

Contact:
Maria
Bharat Book Bureau
810, Real Tech Park,
8th Floor, Sector - 30A,
Vashi, Navi Mumbai - 400703 , INDIA.
Phone: +91-22-27810772, 27810773
Fax:   +91-22-27812290
E-mail: maria@bharatbook.com
Website: http://www.bharatbook.com


'/>"/>
SOURCE Bharat Book Bureau
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Watsons Generic Yaz(R) Receives FDA Approval
2. Watsons Generic BONIVA® 150mg Receives FDA Approval
3. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
4. UBM Conferences Unveils Details for Upcoming Generics and Biosimilars Conference
5. Lupin Receives FDA Approval for Generic LYRICA(R)
6. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. WuXi PharmaTech Announces Third-Quarter 2011 Results
9. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
10. Pharmasset Reports Fiscal Year End 2011 Financial Results
11. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... first-ever genomics analysis platform specifically designed for life science researchers to analyze ... pioneering researcher Rosalind Franklin, who made a major contribution to the discovery ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... today it will be hosting a Webinar titled, “Pathology is going digital. Is ... , on digital pathology adoption best practices and how Proscia improves lab economics ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh ... orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of ... SBT-100 is able to cross the cell membrane and bind intracellular STAT3 and ...
(Date:10/10/2017)... firm Parks Associates announced today that Tom Kerber , ... Meeting , October 11 in Scottsdale, Arizona . Kerber ... smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction ...
Breaking Biology Technology:
(Date:4/18/2017)... 2017  Socionext Inc., a global expert in SoC-based imaging and ... the M820, which features the company,s hybrid codec technology. A demonstration ... Probe, Inc., will be showcased during the upcoming Medtec Japan at ... the Las Vegas Convention Center April 24-27. ... Click here for an ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
Breaking Biology News(10 mins):